223
Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405
Demetzos C, Pippa N (2014) Advanced drug delivery nanosystems (aDDnSs): a mini-review. Drug
Deliv 21:250–257
Doak SH, Griffiths SM, Manshian B, Singh N, Williams PM, Brown AP, Jenkins GJ (2009)
Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24:285–293
Dobrovolskaia MA (2017) Dendrimers effects on the immune system: INSIGHTS into toxicity
and therapeutic utility. Curr Pharm Des
Dobrovolskaia MA, McNeil SE (2013) Understanding the correlation between in vitro and in vivo
immunotoxicity tests for nanomedicines. J Control Release 172:456–466
Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE (2010) Ambiguities
in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle
formulations. Nanomedicine (London) 5:555–562
Dobrovolskaia MA, Shurin M, Shvedova AA (2016) Current understanding of interactions between
nanoparticles and the immune system. Toxicol Appl Pharmacol 299:78–89
Doktorovova S, Souto EB, Silva AM (2014a) Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur J Pharm
Biopharm 87:1–18
Doktorovova S, Santos DL, Costa I, Andreani T, Souto EB, Silva AM (2014b) Cationic solid lipid
nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma
cells. Int J Pharm 471:18–27
Doktorovova S, Silva AM, Gaivao I, Souto EB, Teixeira JP, Martins-Lopes P (2014c) Comet assay
reveals no genotoxicity risk of cationic solid lipid nanoparticles. J Appl Toxicol 34:395–403
Doktorovova S, Kovacevic AB, Garcia ML, Souto EB (2016) Preclinical safety of solid lipid
nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo
evaluation. Eur J Pharm Biopharm 108:235–252
Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJ (2004) Nanotoxicology. Occup Environ
Med 61:727–728
Dong YM, Chen HW, Chen C, Zhang XF, Tian X, Zhang YY, Shi Z, Liu Q (2016) Polymer-lipid
hybrid theranostic nanoparticles co-delivering ultrasmall superparamagnetic iron oxide and
paclitaxel for targeted magnetic resonance imaging and therapy in atherosclerotic plaque. J
Biomed Nanotechnol 12:1245–1257
Du AG, Zykwinska A, Sinquin C, Ratiskol J, Weiss P, Vinatier C, Guicheux J, Delbarre-Ladrat
C, Colliec-Jouault S (2017) Purification of the exopolysaccharide produced by Alteromonas
infernus: identification of endotoxins and effective process to remove them. Appl Microbiol
Biotechnol
Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141
Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, Egea MA, Garcia ML, Souto SB, Souto EB
(2013) A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity
testing. Pharm Dev Technol 18:545–549
Farrera C, Fadeel B (2015) It takes two to tango: understanding the interactions between engineered nanomaterials and the immune system. Eur J Pharm Biopharm 95:3–12
Fisichella M, Berenguer F, Steinmetz G, Auffan M, Rose J, Prat O (2012) Intestinal toxicity evaluation of TiO2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in caco-2 cells. Part Fibre Toxicol 9:18
Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J (2015) Nanostructured lipid (NLCs) carriers as
a bioavailability enhancement tool for oral administration. Drug Deliv 22:691–700
Gonzalez CC, Perez JAR, Perez CAM, Armendariz IO, Vega FJ, Parga KYC, Casillas PEG (2014)
Surface modified superparamagnetic nanoparticles: interaction with fibroblasts in primary cell
culture. J Alloys Compd 615:S655–S659
Gunsolus IL, Haynes CL (2016) Analytical aspects of nanotoxicology. Anal Chem 88:451–479
Hassan S, Singh AV (2014) Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. J Nanosci Nanotechnol 14:402–414
8 In Vitro Methodologies for Toxicological Assessment of Drug Delivery Nanocarriers
Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405
Demetzos C, Pippa N (2014) Advanced drug delivery nanosystems (aDDnSs): a mini-review. Drug
Deliv 21:250–257
Doak SH, Griffiths SM, Manshian B, Singh N, Williams PM, Brown AP, Jenkins GJ (2009)
Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24:285–293
Dobrovolskaia MA (2017) Dendrimers effects on the immune system: INSIGHTS into toxicity
and therapeutic utility. Curr Pharm Des
Dobrovolskaia MA, McNeil SE (2013) Understanding the correlation between in vitro and in vivo
immunotoxicity tests for nanomedicines. J Control Release 172:456–466
Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE (2010) Ambiguities
in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle
formulations. Nanomedicine (London) 5:555–562
Dobrovolskaia MA, Shurin M, Shvedova AA (2016) Current understanding of interactions between
nanoparticles and the immune system. Toxicol Appl Pharmacol 299:78–89
Doktorovova S, Souto EB, Silva AM (2014a) Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur J Pharm
Biopharm 87:1–18
Doktorovova S, Santos DL, Costa I, Andreani T, Souto EB, Silva AM (2014b) Cationic solid lipid
nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma
cells. Int J Pharm 471:18–27
Doktorovova S, Silva AM, Gaivao I, Souto EB, Teixeira JP, Martins-Lopes P (2014c) Comet assay
reveals no genotoxicity risk of cationic solid lipid nanoparticles. J Appl Toxicol 34:395–403
Doktorovova S, Kovacevic AB, Garcia ML, Souto EB (2016) Preclinical safety of solid lipid
nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo
evaluation. Eur J Pharm Biopharm 108:235–252
Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJ (2004) Nanotoxicology. Occup Environ
Med 61:727–728
Dong YM, Chen HW, Chen C, Zhang XF, Tian X, Zhang YY, Shi Z, Liu Q (2016) Polymer-lipid
hybrid theranostic nanoparticles co-delivering ultrasmall superparamagnetic iron oxide and
paclitaxel for targeted magnetic resonance imaging and therapy in atherosclerotic plaque. J
Biomed Nanotechnol 12:1245–1257
Du AG, Zykwinska A, Sinquin C, Ratiskol J, Weiss P, Vinatier C, Guicheux J, Delbarre-Ladrat
C, Colliec-Jouault S (2017) Purification of the exopolysaccharide produced by Alteromonas
infernus: identification of endotoxins and effective process to remove them. Appl Microbiol
Biotechnol
Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141
Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, Egea MA, Garcia ML, Souto SB, Souto EB
(2013) A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity
testing. Pharm Dev Technol 18:545–549
Farrera C, Fadeel B (2015) It takes two to tango: understanding the interactions between engineered nanomaterials and the immune system. Eur J Pharm Biopharm 95:3–12
Fisichella M, Berenguer F, Steinmetz G, Auffan M, Rose J, Prat O (2012) Intestinal toxicity evaluation of TiO2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in caco-2 cells. Part Fibre Toxicol 9:18
Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J (2015) Nanostructured lipid (NLCs) carriers as
a bioavailability enhancement tool for oral administration. Drug Deliv 22:691–700
Gonzalez CC, Perez JAR, Perez CAM, Armendariz IO, Vega FJ, Parga KYC, Casillas PEG (2014)
Surface modified superparamagnetic nanoparticles: interaction with fibroblasts in primary cell
culture. J Alloys Compd 615:S655–S659
Gunsolus IL, Haynes CL (2016) Analytical aspects of nanotoxicology. Anal Chem 88:451–479
Hassan S, Singh AV (2014) Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. J Nanosci Nanotechnol 14:402–414
8 In Vitro Methodologies for Toxicological Assessment of Drug Delivery Nanocarriers